Abstract
BackgroundRituximab is a genetically engineered chimeric murine/human monoclonal immunoglobulin (Ig) G1 κ-antibody directed against the CD20 antigen of B-cells. PF-05280586, a proposed biosimilar to rituximab, was studied in a double-blind...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
